A Cross-Protective Vaccine Against 4b and 1/2b Listeria monocytogenes

Frontiers in Microbiology

卷:11

Guo Li²  Jing Li²  Xin’an Jiao²  Tengfei Zhu²  Chuang Meng²  Yuelan Yin²  Youwei Feng²  Fanzeng Meng²  Zhiting Ling²  Xinyu Sun²  Jiaqi Chen²  Hao Yao² 

[1] Jangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China;

[2] Jiangsu Co-innovation Center for the Prevention and Control of Important Animal Infectious Disease and Zoonosis, Yangzhou University, Yangzhou, China;

[3] Joint International Research Laboratory of Agriculture and Agri-Product Safety of the Ministry of Education of China, Yangzhou University, Yangzhou, China;

[4] Key Laboratory of Prevention and Control of Biological Hazard Factors (Animal Origin) for Agrifood Safety and Quality, The Ministry of Agriculture of China, Yangzhou University, Yangzhou, China;

关键词: Listeria monocytogenes;    attenuated vaccine;    cellular immune response;    cross protection;    humoral immune response;   

DOI  :  10.3389/fmicb.2020.569544

来源: DOAJ

【 摘 要 】

Listeria monocytogenes (Lm) is a foodborne zoonotic pathogen that causes listeriosis with a mortality rate of 20–30%. Serovar 4b and 1/2b isolates account for most of listeriosis outbreaks, however, no listeriosis vaccine is available for either prophylactic or therapeutic use. Here, we developed a triple-virulence-genes deletion vaccine strain, and evaluated its safety, immunogenicity, and cross-protective efficiency. The virulence of NTSNΔactA/plcB/orfX was reduced 794-folds compared with the parental strain. Additionally, it was completely eliminated in mice at day 7 post infection and no obvious pathological changes were observed in the organs of mice after prime-boost immunization for 23 days. These results proved that the safety of the Lm vaccine strain remarkably increased. More importantly, the NTSNΔactA/plcB/orfX strain stimulated higher anti-Listeriolysin O (LLO) antibodies, induced significantly higher expression of IFN-γ, TNF-α, IL-17, and IL-6 than the control group, and afforded 100% protection against serovar 4b and 1/2b challenges. Taken together, our research demonstrates that the triple-genes-deletion vaccine has high safety, can elicit strong Th1 type immune response, and affords efficient cross-protection against two serovar Lm strains. It is a promising vaccine for prevention of listeriosis.

【 授权许可】

Unknown